Novavax Receives the US FDA’s Fast Track Designation for NVX-CoV2373 to Treat COVID-19

Shots:

• The US FDA has granted FT designation to NVX-CoV2373 which is currently in late-phase clinical development. Novavax expects to initiate pivotal P-III study in the US & Mexico by the end of Nov’2020
• The company’s ongoing P-lll trial in the UK to evaluate the efficacy, safety, and immunogenicity of NVX-CoV2373 is expected to be fully enrolled by the end of Nov. Depending on the overall COVID-19 attack rate, interim data in the UK trial is expected in Q1’21
• NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant

Click here ­to­ read full press release/ article | Ref: Novavax | Image: Newsroom Keck Medicine of USC